Timing of intrathecal chemotherapy and blinatumomab impacts neurotoxicity in acute lymphoblastic leukemia.
作者信息
Lee Benjamin J, Griffin Shawn P, Doh Jean, Kongtim Piyanuch, Chan Alexandre, O'Brien Susan, Jeyakumar Deepa, Ciurea Stefan O
机构信息
Department of Pharmacy, Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, USA.
Department of Clinical Pharmacy Practice, School of Pharmacy & Pharmaceutical Sciences, University of California, Irvine, California, USA.
出版信息
Am J Hematol. 2023 May;98(5):E113-E115. doi: 10.1002/ajh.26880. Epub 2023 Feb 24.
PMID:36794446
Abstract
摘要
相似文献
1
Timing of intrathecal chemotherapy and blinatumomab impacts neurotoxicity in acute lymphoblastic leukemia.鞘内化疗和博纳吐单抗的给药时机对急性淋巴细胞白血病的神经毒性有影响。
Am J Hematol. 2023 May;98(5):E113-E115. doi: 10.1002/ajh.26880. Epub 2023 Feb 24.
2
The safety of concurrent intrathecal chemotherapy during blinatumomab in adults with acute lymphoblastic leukemia.在成人急性淋巴细胞白血病患者中，blinatumomab治疗期间鞘内化疗的安全性。
Leuk Lymphoma. 2022 Nov;63(11):2754-2756. doi: 10.1080/10428194.2022.2090555. Epub 2022 Jun 21.
3
Delayed-onset severe neurotoxicity related to blinatumomab in an adolescent patient with refractory acute lymphoblastic leukemia.一名患有难治性急性淋巴细胞白血病的青少年患者中与博纳吐单抗相关的迟发性严重神经毒性。
Pediatr Blood Cancer. 2021 Jul;68(7):e29040. doi: 10.1002/pbc.29040. Epub 2021 Mar 31.
4
Building a better blinatumomab.打造更好的博纳吐单抗。
Am J Hematol. 2024 Apr;99(4):512-514. doi: 10.1002/ajh.27253. Epub 2024 Feb 16.
5
Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab.接受双特异性T细胞衔接器blinatumomab治疗的急性淋巴细胞白血病患者的皮肤不良事件。
Leuk Lymphoma. 2023 Sep;64(9):1583-1587. doi: 10.1080/10428194.2023.2221756. Epub 2023 Jun 12.
6
Is blinatumomab now standard of care consolidation for patients with ALL?对于急性淋巴细胞白血病（ALL）患者，博纳吐单抗现在是巩固治疗的标准疗法吗？
Clin Adv Hematol Oncol. 2023 Jun;21(6):281-283.
7
[Analysis on the clinical efficacy and adverse reactions of blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia].[博纳吐单抗治疗复发/难治性急性淋巴细胞白血病的临床疗效及不良反应分析]
Zhonghua Xue Ye Xue Za Zhi. 2023 Jun 14;44(6):516-519. doi: 10.3760/cma.j.issn.0253-2727.2023.06.015.
8
CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis.复发/难治性B细胞前体急性淋巴细胞白血病成年患者接受博纳吐单抗治疗后出现CD19阴性复发——一项事后分析
Am J Hematol. 2023 Aug;98(8):E222-E225. doi: 10.1002/ajh.26988. Epub 2023 Jun 22.
9
Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.blinatumomab 治疗复发/难治性 B 细胞前体急性淋巴细胞白血病的获益-风险评估。
Drug Saf. 2019 May;42(5):587-601. doi: 10.1007/s40264-018-0760-1.
10
Bispecific antibodies in acute lymphoblastic leukemia therapy.双特异性抗体在急性淋巴细胞白血病治疗中的应用。
Expert Rev Hematol. 2020 Nov;13(11):1211-1233. doi: 10.1080/17474086.2020.1831380. Epub 2020 Nov 4.
引用本文的文献
1
Blinatumomab in Children with MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 11 Cases.博纳吐单抗治疗微小残留病阳性的B细胞前体急性淋巴细胞白血病患儿：11例报告
Hematol Rep. 2024 Jun 3;16(2):347-353. doi: 10.3390/hematolrep16020035.
Zotero 插件